 |
|
|
| |
SAPPHIRE-II Subgroup Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-experienced Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics
|
| |
| |
Reported by Jules Levin
20th International AIDS Conference, 20-25 July, 2014, Melbourne, Australia
Simone I Strasser1, Kosh Agarwal2, Moises Diago3, Igor Bakulin4, Giovanni B Gaeta5, Albrecht Stoehr6, Jean-Pierre Zarski7, Junyuan Xiong8, Lois Larsen8, Tolga Baykal8, Jeff rey Enejosa8, Daniel E Cohen8, Thomas Podsadecki8
1AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; 2Institute of Liver Studies, Kings College Hospital, London, United Kingdom; 3Hospital Quiron de Valencia, Valencia, Spain; 4Moscow Scientific Clinical Center, Moscow, Russia; 5A.O.U. Seconda Universita degli Studi di Napoli, Naples, Italy; 6ifi -Studien und Projekte GmbH, Hamburg, Germany; 7CHU de Grenoble, Grenoble, France; 8AbbVie Inc., North Chicago, Illinois, United States.
These are links to the phase 3 studies reported at EASL in April including for this subpopulation analysis of the SAPPHIRE-2 Study:
EASL: SAPPHIRE-I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAïVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/11/14)
EASL: SAPPHIRE-II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/r/ABT-267, ABT-333, AND RIBAVIRIN IN 394 TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 - (04/10/14)
EASL: TURQUOISE-II: SVR12 RATE OF 92-96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/r/ABT-267 AND ABT-333 PLUS RIBAVIRIN - (04/14/14)
|
| |
|
|
|
|
|
